US 11,752,343 B2
Peripheral nerve field stimulation control
Gary W. King, Fridley, MN (US); Steven M. Goetz, North Oaks, MN (US); Andrew H. Houchins, Hugo, MN (US); Jeffrey T. Keacher, Stanford, CA (US); Jordan J. Greenberg, Blaine, MN (US); Kenneth T. Heruth, Edina, MN (US); Mark S. Lent, Brooklyn Park, MN (US); and Paul W. Wacnik, Brookline, MA (US)
Assigned to Medtronic, Inc., Minneapolis, MN (US)
Filed by Medtronic, Inc., Minneapolis, MN (US)
Filed on Aug. 5, 2020, as Appl. No. 16/985,955.
Application 16/985,955 is a division of application No. 14/454,427, filed on Aug. 7, 2014, granted, now 10,744,326.
Application 14/454,427 is a continuation of application No. 12/359,001, filed on Jan. 23, 2009, granted, now 8,805,518, issued on Aug. 12, 2014.
Claims priority of provisional application 61/051,955, filed on May 9, 2008.
Prior Publication US 2020/0368532 A1, Nov. 26, 2020
Int. Cl. A61N 1/36 (2006.01)
CPC A61N 1/36139 (2013.01) [A61N 1/36057 (2013.01); A61N 1/36071 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A method comprising:
delivering peripheral nerve field stimulation to a region of a body of a patient in which the patient experiences pain via at least one electrode implanted in the region;
receiving a signal indicative of a physiological parameter of the patient;
determining the patient pain state based on the signal; and
based on the patient pain state, controlling the delivery of peripheral nerve field stimulation to a region of a body of the patient in which the patient experiences pain via at least one electrode implanted in the region, wherein controlling the delivery of the peripheral nerve field stimulation comprises deactivating the delivery of the peripheral nerve field stimulation to the region of the body and wherein the peripheral nerve field stimulation is not deliberately targeting a specific nerve.